{
    "nct_id": "NCT03541720",
    "official_title": "18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma",
    "inclusion_criteria": "Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. 18F-DA PET/CT scanning will not be the initial imaging study in a newly diagnosed patient.\n\nPatients with positive findings on prior imaging within the past 4 weeks are eligible.\n\nPrior therapy is allowed.\n\nPatients > 1 year of age, under the care of a SJCRH physician.\n\nPatients of both genders, and all ethnic groups, under the care of a SJCRH physician.\n\nFemale participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.\n\nInformed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board.\n\nPatients may undergo a repeat study one or more years following the initial FLOPET scan.\nHealthy volunteers allowed\nMust have minimum age of 1 Year",
    "exclusion_criteria": "Inability or unwillingness of patient, parent, or guardian to consent.\n\nPregnancy or lactation. Future plans for pregnancy do not exclude patient participation. Patients should not become pregnant within one month of completion of 18F-DA PET scan.\n\nUse of medications known to interfere with 123I-mIBG uptake (principal considerations are phenylephrine and pseudoephedrine containing compounds which need to be discontinued for 48 hours, and labetalol which needs to be discontinued for 6 weeks).\n\nPatients less than 3 years of age who require a total length of anesthesia time greater than 3 hours (for the FLOPET scan in conjunction with another clinical procedure requiring sedation) will be excluded from the study.",
    "miscellaneous_criteria": ""
}